Microplate DX
Rapid antibiotic susceptibility testing technology for clinicians treating urinary tract infections
Highlights
- New on EvolcAdded 2026-11-13
About Microplate DX
Microplate Dx develops RapidPlate, a diagnostic platform combining biosensor hardware and data-processing algorithms to test antibiotic susceptibility in patient samples. Its current focus is urinary tract infections, with plans to expand the platform to other infectious diseases.
The Glasgow-based company was founded in 2021 and conducts clinical development in collaboration with the NHS. Its team includes expertise across medicine, science, engineering and technology.
Product: RapidPlate, a biosensor-based platform for rapid antibiotic susceptibility testing and bacterial species identification.
Jobs at Microplate DX
Leadership
- Stuart Hannah · Chief Executive OfficerSource: company website
More health & medtech companies
Microsensdx
Develops a blood test for sepsis diagnosis and risk profiling, alongside sample preparation products and services for diagnosticsNew on EvolcMidco Care
Home care, supported living and healthcare staffing across the UK for local authorities, NHS Trusts and care homesSalary transparentMiddleton Grove
Residential and day care for older adults in Hove, East SussexMidway Care Group
Residential and supported living care for people with learning disabilities and additional needs in the West MidlandsNew on EvolcMiim Media
A picture-based messaging language and app for people with communication and learning difficultiesNew on EvolcMikkom
Healthcare booking, patient portal and digital voucher systems for NHS, private healthcare and workplace health providersNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
No confirmed website technologies in the latest recorded checks.
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.